Mesenchymal stem cell infusion for enhancing hematopoietic recovery and addressing cytopenias in CAR-T cell therapy
1 Cytopenia is a frequently observed adverse effect following CAR-T therapy, and it is often characterized by biphasic and prolonged patterns. 2 MSCs play a critical role in promoting hematopoietic recovery and mitigating bone marrow damage in a murine model of CAR-T therapy 3 The activity and antitumor efficacy of CAR-T cells were not impaired by MSCs.
Authors
- Lei Fan (ORCID: https://orcid.org/0000-0002-9368-4987)
- Xuxing Shen (ORCID: https://orcid.org/0000-0003-0110-1463)
- Ying Xu (ORCID: https://orcid.org/0000-0003-3563-4233)
- Yuan Xia (ORCID: https://orcid.org/0000-0002-8061-4955)
- Lijuan Chen (ORCID: https://orcid.org/0000-0002-6497-1194)
- Jianyong Li (ORCID: https://orcid.org/0000-0002-9931-4055)
- Wei Xu (ORCID: https://orcid.org/0000-0002-5826-3730)
- Li Wang (ORCID: https://orcid.org/0000-0002-0496-9500)
Institutions
- Nantong University (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Stem Cell Research & Therapy
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s13287-024-03941-8
- Citations
- 7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- National Natural Science Foundation of China
- Nanjing Medical University